These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27796466)

  • 1. Randomised trial of the effect of a gastrin/CCK
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
    Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
    Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
    Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
    PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
    Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
    Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
    Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
    Boyce M; Warrington S
    Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
    Boyce M; Warrington S; Black J
    Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response: Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.
    Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
    Eur J Clin Pharmacol; 2017 Jul; 73(7):925. PubMed ID: 28365794
    [No Abstract]   [Full Text] [Related]  

  • 9. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
    Aasarød KM; Ramezanzadehkoldeh M; Shabestari M; Mosti MP; Stunes AK; Reseland JE; Beisvag V; Eriksen EF; Sandvik AK; Erben RG; Schüler C; Boyce M; Skallerud BH; Syversen U; Fossmark R
    J Endocrinol; 2016 Aug; 230(2):251-62. PubMed ID: 27325243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Controlled Trial of the Gastrin/CCK
    Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
    Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis.
    Håkanson R; Ding XQ; Norlén P; Lindström E
    Regul Pept; 1999 Mar; 80(1-2):1-12. PubMed ID: 10235629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
    Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
    Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
    Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-course of deactivation of rat stomach ECL cells following cholecystokinin B/gastrin receptor blockade.
    Ding XQ; Lindström E; Håkanson R
    Br J Pharmacol; 1997 Sep; 122(1):1-6. PubMed ID: 9298521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
    Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
    Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: a gastrin antagonist against carcinoids--implications for PPI-induced hypergastrinaemia.
    McCarthy DM
    Aliment Pharmacol Ther; 2013 Jan; 37(2):276-7. PubMed ID: 23252778
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.
    Fossmark R; Jianu CS; Martinsen TC; Qvigstad G; Syversen U; Waldum HL
    Scand J Gastroenterol; 2008 Jan; 43(1):20-4. PubMed ID: 18938772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
    Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
    Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
    Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
    Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin].
    Kim BW; Lee BI; Kim HK; Cho YS; Chae HS; Lee HK; Kim HJ; Han SW
    Korean J Gastroenterol; 2009 Feb; 53(2):84-9. PubMed ID: 19237833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.